跳至主要内容
临床试验/EUCTR2012-003923-39-GB
EUCTR2012-003923-39-GB进行中(未招募)1 期

Pilot study to evaluate whether treating persistent small airway dysfunction with extra-fine HFA-Beclometasone results in improved asthma control. - Targeted small airways therapy in persistent asthma ANDA3

Tayside Medical Science Centre0 个研究点目标入组 74 人开始时间: 2013年6月3日最近更新:
适应症
相关药物

试验速览

阶段
1 期
状态
进行中(未招募)
发起方
入组人数
74

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

入选标准

  • Male and female volunteers aged 18-65, with persistent asthma.
  • Asthma Control Questionnaire score >1.0 (at end of run-in)
  • Spirometry: FEV1 >60% predicted.
  • Impulse oscillometry: R5>130% predicted and R5-R20>0.03kPa/L/s.
  • Ability to perform spirometry, IOS, bronchial challenge and all domiciliary measurements.
  • Ability to give informed consent.
  • Asthmatic patients receiving treatment at Step 2, 3, or 4 of BTS asthma guidelines.
  • Ability to withhold long acting beta 2 agonists for the duration of the study.
  • Are the trial subjects under 18? no
  • Number of subjects for this age range: 0
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 23
  • F.1.3 Elderly (>=65 years) no
  • F.1.3.1 Number of subjects for this age range 0

排除标准

  • Pregnancy or lactation.
  • Known or suspected sensitivity to the IMP(s).
  • Inability to comply with protocol.
  • Any clinically significant medical conditions that may either endanger the health or safety of the participant, or jeopardise the protocol.
  • An asthma exacerbation requiring systemic steroid therapy or lower respiratory tract infection requiring antibiotics within 3 months prior to study commencement.
  • Participation in previous trial within 30 days.

研究者

发起方
Tayside Medical Science Centre

相似试验